The American College of Physicians (ACP) has issued a new guideline regarding treatment of osteoporosis to prevent fracture. 

Among other things, the guideline offers a strong recommendation that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis, and a strong recommendation against the use of menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for treatment of osteoporosis in women. Learn more...

Comments (0)

There are no comments posted here yet

Submit Community Content

If you have orthopedic information that you would like to share with the Orthogate Community, please register/login and submit your news, event, job, article, case or workshop from the Submit Content menu under the My Account area. Learn more!